Last quarter (Q4 2023), Innate Pharma's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, Innate Pharma's net income was €―. See Innate Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	€ 61.64M	€ 57.67M	€ 24.70M	€ 56.16M	€ 68.97M
Cost of Revenue	-	-	€ -115.10M	€ 4.00M	€ 3.04M	€ 757.00K
Gross Profit	-	€ 61.64M	€ 57.62M	€ 20.71M	€ 53.79M	€ 68.22M
Operating Expense	-	€ 74.31M	€ 74.10M	€ 72.53M	€ 55.08M	€ 95.27M
Operating Income	-	€ -12.67M	€ -16.48M	€ -51.82M	€ 1.08M	€ -27.05M
Net Non Operating Interest Income Expense	-	€ 2.99M	€ 4.78M	€ 6.34M	€ 223.00K	€ 1.43M
Other Income Expense	-	-	€ -59.00K	€ -28.70M	€ -2.13M	€ 4.86M
Pretax Income	-	€ -7.57M	€ -57.97M	€ -45.48M	€ -829.00K	€ -20.76M
Tax Provision	-	-	-	-	€ 0.00	€ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ -7.57M	€ -58.10M	€ -52.81M	€ -63.98M	€ -20.76M
Basic EPS	-	€ -0.09	€ -0.73	€ -0.66	-	-
Diluted EPS	-	€ -0.09	€ -0.73	€ -0.66	-	-
Basic Average Shares	-	€ 80.45B	€ 79.64M	€ 79.54M	-	-
Diluted Average Shares	-	€ 80.45B	€ 79.59M	€ 80.01M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	€ 1.70M	€ 1.03M
Total Expenses	-	€ 74.31M	€ -41.00M	€ 76.53M	€ 55.08M	€ 96.03M
Net Income From Continuing And Discontinued Operation	-	€ -7.57M	€ -58.10M	€ -52.81M	€ -63.98M	€ -20.76M
Normalized Income	-	-	-	-	€ 1.30M	€ -25.62M
Interest Expense	-	-	-	-	€ 341.00K	€ 204.00K
EBIT	-	-	€ -58.26M	€ -45.48M	€ -488.00K	€ -20.55M
EBITDA	-	-	€ -12.86M	€ -40.88M	€ 56.31M	€ -4.03M

Currency in EUR

Innate Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing